Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Faropenem Sodium: Broad-Spectrum Penem Antibiotic for Ant...

    2026-02-18

    Faropenem Sodium: Broad-Spectrum Penem Antibiotic for Antimicrobial Research

    Executive Summary: Faropenem sodium (CAS No. 122547-49-3) is a penem-class β-lactam antibiotic with broad-spectrum antimicrobial activity, including potent efficacy against Gram-positive, Gram-negative, and anaerobic bacteria (Uchino et al., 2000). The compound is orally bioavailable and is absorbed through a carrier-mediated system in the small intestine, independent of food intake (APExBIO). Faropenem sodium exhibits significant stability against β-lactamases and dehydropeptidase-I, addressing a major mechanism of antibiotic resistance. Renal secretion is mediated by the inorganic phosphate transporter Npt1, providing a clear pharmacokinetic profile. Comparative in vitro studies report minimum inhibitory concentrations (MICs) as low as 0.78 μg/mL for clinical isolates, establishing its benchmark efficacy (Uchino et al., 2000).

    Biological Rationale

    Faropenem sodium is a non-classical β-lactam antibiotic in the penem subclass. It is structurally characterized by the presence of a 4:5 fused β-lactam ring and a sulfur atom at position 1, distinguishing it from carbapenems and penicillins (APExBIO). The compound exhibits a broad antimicrobial spectrum, with activity against Staphylococcus spp., Streptococcus spp., Haemophilus influenzae, Neisseria gonorrhoeae, and Branhamella catarrhalis. Notably, it demonstrates high potency against anaerobic pathogens and is stable in the presence of β-lactamases, enzymes commonly responsible for bacterial resistance to β-lactam antibiotics. These properties make Faropenem sodium a preferred tool for research on antibiotic resistance, cell wall synthesis inhibition, and infection models involving mixed bacterial populations (Faropenem Sodium: Penem Antibiotic for Broad-Spectrum Antimicrobial Research - this article further details workflows and experimental strategies for the C8712 kit, extending the mechanistic focus outlined here).

    Mechanism of Action of Faropenem sodium

    Faropenem sodium exerts its bactericidal effect by inhibiting bacterial cell wall synthesis. It achieves this by binding with high affinity to penicillin-binding proteins (PBPs), which are essential enzymes in the peptidoglycan cross-linking process. By blocking PBPs, Faropenem sodium disrupts cell wall construction, leading to osmotic instability and bacterial lysis (Uchino et al., 2000). The compound's stability against β-lactamase enzymes, including both serine- and metallo-β-lactamases, is attributed to its unique chemical structure. Additionally, Faropenem sodium is resistant to dehydropeptidase-I (DHP-I) hydrolysis, which further extends its antimicrobial spectrum compared to many classical β-lactams (Faropenem Sodium: Broad-Spectrum Penem Antibiotic for Research—this article provides clinical benchmarks, while the present piece emphasizes experimental and mechanistic details).

    Evidence & Benchmarks

    • Faropenem sodium is actively transported across the renal epithelial luminal membrane by the inorganic phosphate transporter Npt1, with a Michaelis-Menten constant (Km) of 0.77 ± 0.34 mM (pH 7.4, 25°C) (Uchino et al., 2000).
    • In vitro, Faropenem sodium demonstrates minimum inhibitory concentrations (MICs) as low as 0.78 μg/mL against clinical isolates of anaerobic bacteria (aerobic and anaerobic conditions, 37°C, 18–24 h) (APExBIO).
    • The compound remains stable against hydrolysis by β-lactamases and DHP-I, as demonstrated by enzymatic assays (buffered at pH 7.2, 37°C, 60 min) (Faropenem Sodium: Next-Generation Anti-Anaerobic β-Lactam).
    • Carrier-mediated absorption occurs in the small intestine, and oral bioavailability is not affected by food intake (fasted/fed crossover studies, human volunteers) (APExBIO).
    • Renal elimination is the exclusive route of excretion, mediated by Npt1, as confirmed in Xenopus oocyte models expressing the transporter (oocyte uptake and efflux assays, 18°C) (Uchino et al., 2000).
    • Faropenem sodium exhibits superior anti-anaerobic activity compared to cefteram, cefixime, amoxicillin, and metronidazole (MIC comparison, standardized CLSI protocols) (Faropenem Sodium: Mechanistic Foundations and Translational Applications—this article is extended here with additional transport and pharmacokinetic evidence).

    Applications, Limits & Misconceptions

    Faropenem sodium is widely used in research on antimicrobial resistance, infection modeling, and pharmacokinetic studies involving both Gram-positive and Gram-negative organisms, as well as anaerobic pathogens. Its high oral bioavailability and β-lactamase stability make it suitable for studies where conventional β-lactams fail due to resistance or enzymatic degradation. The compound's pharmacokinetics, characterized by exclusive renal elimination, provide clarity for dose-response and distribution experiments (Uchino et al., 2000). Researchers should note that while Faropenem sodium is highly stable, long-term storage of solutions is not recommended; it should be stored sealed and dry at -20°C (APExBIO).

    Common Pitfalls or Misconceptions

    • Faropenem sodium is not effective against organisms with altered PBPs that severely reduce binding affinity (e.g., some MRSA and penicillin-resistant pneumococci).
    • It does not inhibit non-bacterial pathogens such as fungi or viruses.
    • Renal impairment may alter pharmacokinetics; dose adjustments or alternative models are required for accurate interpretation.
    • Long-term solution storage (>7 days, even at -20°C) may lead to degradation and reduced activity.
    • Its efficacy should not be generalized to all β-lactam-resistant strains without specific susceptibility testing.

    Workflow Integration & Parameters

    Faropenem sodium (SKU C8712) from APExBIO is supplied as a powder, soluble in DMSO. For most in vitro assays, a working concentration range of 0.5–32 μg/mL is recommended, depending on the target organism and assay design. Solutions should be freshly prepared and filtered before use. Store the compound at -20°C under desiccated, sealed conditions to maintain stability. For oral bioavailability studies, administer in buffered solution, and for parenteral models, monitor serum and interstitial concentrations at 0.5, 1, 2, and 4 hours post-dosing. The compound integrates seamlessly into resistance profiling, cell wall synthesis inhibition, and infection model workflows (Faropenem Sodium: Broad-Spectrum Penem Antibiotic for AMR Studies—the present article adds updated mechanistic and transporter data for workflow optimization).

    Conclusion & Outlook

    Faropenem sodium is a next-generation, broad-spectrum penem antibiotic suited for advanced antimicrobial research. Its unique absorption and elimination profiles, together with β-lactamase and DHP-I stability, make it a robust tool for studying cell wall synthesis inhibition and bacterial resistance mechanisms. Ongoing research is expected to further delineate its utility in multi-drug resistance and pharmacokinetic modeling. For additional details and procurement, visit the Faropenem sodium product page from APExBIO.